Previous close | 1,154.00 |
Open | 1,161.50 |
Bid | 1,152.00 x N/A |
Ask | 1,168.00 x N/A |
Day's range | 1,161.00 - 1,162.00 |
52-week range | 875.00 - 1,304.00 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0% and 4.92%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Mettler-Toledo's (MTD) first-quarter performance is likely to reflect the adverse impacts of macroeconomic headwinds, and weak momentum across the Industrial and Laboratory segments.
Beyond analysts' top -and-bottom-line estimates for Mettler-Toledo (MTD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.